Navigation Links
Telik Announces Initiation of Phase 1 Clinical Study of Ezatiostat Hydrochloride (TELINTRA(R), TLK199) Tablets in Combination With Lenalidomide (Revlimid(R)) in Patients With Myelodysplastic Syndrome (MDS)
Date:1/25/2010

s with Severe Chronic Idiopathic Neutropenia (SCIN).

Background on MDS and TELINTRA

MDS is a heterogeneous group of blood stem cell disorders of increasing incidence.  MDS is characterized by ineffective blood cell production involving one or more of the red cell, white cell or platelet lineages and with MDS patients having a variable risk of progression to leukemia.  There remains a need for effective, well tolerated therapies for MDS having novel mechanisms of action.  TELINTRA has a novel mechanism of action that inhibits a target enzyme called glutathione S-transferase P1-1 which in turn facilitates the activation of JNK kinase, a key regulator of cellular growth and differentiation of blood.  TELINTRA has been shown to stimulate normal multilineage differentiation of blood stem cell precursors and induce cancer cell death in human leukemia cell lines.  Additional information on TELINTRA is available at www.telik.com.

About Telik

Telik, Inc. of Palo Alto, CA, is a clinical stage drug development company focused on discovering and developing small molecule drugs to treat cancer and inflammatory diseases.  The company's most advanced investigational drug candidates in clinical development are TELINTRA, a modified glutathione analog for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy, and TELCYTA®, a tumor-activated prodrug for the treatment of advanced ovarian cancer and non-small cell lung cancer.  Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP®, which enables the rapid and efficient discovery of small molecule drug candidates.


'/>"/>
SOURCE Telik, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Telik Announces Presentation of Preclinical Data on Dual Inhibitors of Aurora Kinases and VEGFR2
2. Telik Announces Preclinical Data Demonstrating Anti-Cancer Activity of Dual Inhibitors of Aurora Kinase and VEGFR2
3. Telik Announces Telintra Presentation at American Society of Hematology Annual Meeting
4. Telik Announces Initiation of Two Phase 2 Randomized TELINTRA Studies
5. Teliks Proteasome Inhibitor Program Meets a Preclinical Development Milestone
6. Telik Announces Presentation at ASCO Annual Meeting
7. Telik Announces Publication of Positive Phase 1 Results of a Multicenter Study of Ezatiostat Hydrochloride (TELINTRA(R), TLK199) Tablets In Patients With Myelodysplastic Syndrome
8. Telik Announces Publication of Positive Phase 1-2a Results of a Multicenter Study of TELCYTA(R) in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer
9. Telik Announces Third Quarter 2009 Financial Results
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... , Aug. 28, 2014  Sequent Medical, ... enrollment in an Investigational Device Exemption ("IDE") pivotal ... the WEB™ Aneurysm Embolization System ("WEB"). Adam ... Department of Neurosurgery/Semmes-Murphey Clinic and Principal Investigator of ... the study, treating them with the WEB at ...
(Date:8/28/2014)... 28, 2014 GenSpera, Inc. (OTCQB: GNSZ), a ... cancer, announces the recent publication of the article "Targeting ... The recent article co-authored by Doan, et ... of GenSpera,s prodrug technology platform that is designed to ... plant Thapsia garganica ) directly to tumors. These ...
(Date:8/28/2014)... , Aug. 28, 2014 Synthetic ... novel anti-infective biologic and drug candidates targeting specific ... FUJIFILM Diosynth Biotechnologies UK Limited (Fujifilm), announced today ... of cGMP manufacturing of SYN-004, Synthetic Biologics, proprietary ... Clostridium difficile ( C. difficile ) infections. ...
Breaking Medicine Technology:Sequent Medical Announces Initiation Of IDE Study For The WEB Aneurysm Embolization System 2Sequent Medical Announces Initiation Of IDE Study For The WEB Aneurysm Embolization System 3GenSpera Media Advisory; "Targeting thapsigargin towards tumors" Published in Steroids 2GenSpera Media Advisory; "Targeting thapsigargin towards tumors" Published in Steroids 3Synthetic Biologics and FUJIFILM Diosynth Biotechnologies UK Announce Significant Improvement in API Manufacturing of SYN-004 for the Prevention of C. difficile 2Synthetic Biologics and FUJIFILM Diosynth Biotechnologies UK Announce Significant Improvement in API Manufacturing of SYN-004 for the Prevention of C. difficile 3Synthetic Biologics and FUJIFILM Diosynth Biotechnologies UK Announce Significant Improvement in API Manufacturing of SYN-004 for the Prevention of C. difficile 4Synthetic Biologics and FUJIFILM Diosynth Biotechnologies UK Announce Significant Improvement in API Manufacturing of SYN-004 for the Prevention of C. difficile 5
... TRACON Pharmaceuticals, a biotechnology company that develops targeted ... Phase 1 clinical results from studies of TRC105 and ... at the American Society of Clinical Oncology annual meeting ... programs target unique pathways with the potential for broad ...
... Ascenta Therapeutics announced today that eleven presentations or publications ... pan-Bcl-2 inhibitor, in several major tumor types will be ... (ASCO) Annual Meeting, May 29-June 2, in Orlando, Florida. ... .(Logo: http://www.newscom.com/cgi-bin/prnh/20090227/PH75873LOGO ...
Cached Medicine Technology:TRACON Pharmaceuticals' Small Molecule TRC102 and Antibody TRC105 to be Presented at ASCO 2009 2Ascenta Therapeutics Announces Multiple Presentations on AT-101 at 2009 ASCO Annual Meeting 2Ascenta Therapeutics Announces Multiple Presentations on AT-101 at 2009 ASCO Annual Meeting 3
(Date:8/28/2014)... new study from Northwestern Medicine has found that surgical researchers ... studies -- despite a huge body of evidence showing that ... , Editors of the five major surgical journals reviewed in ... require authors to state the sex of animals and cells ... in their studies, they will be asked to justify why. ...
(Date:8/28/2014)... (Aug. 28, 2014) Solid-head power toothbrushes ... to researchers at The University of Texas Health ... The results of the study are published in ... Hygiene. Lead author and professor at the UTHealth ... notes that microbial counts were lower in the ...
(Date:8/28/2014)... about datahow to gather it, organize it, and ... analyze and share data lies at the heart ... storage, and analysis of biochemical and biological information ... used in bioinformatics have been instrumental in the ... genomics. But, in the plant sciences, bioinformatics and ...
(Date:8/28/2014)... 28, 2014 Save On Medical ... accelerator program in Tampa. Healthbox Florida has teamed ... companies grow and achieve their goals. , Healthbox ... at their launch event at the Mahaffey Theater to ... Co-founder Matt Schneider commented on the Save On Medical’s ...
(Date:8/28/2014)... Beach, CA (PRWEB) August 28, 2014 ... returns to the more than 100 million people who ... Medicine Report from the Committee on Advancing Pain Research, ... National Institutes of Health, is defined as any pain ... or even longer. And while chronic pain causes range ...
Breaking Medicine News(10 mins):Health News:Females ignored in basic medical research 2Health News:Females ignored in basic medical research 3Health News:UTHealth researchers find up to 3,000 times the bacterial growth on hollow-head toothbrushes 2Health News:Together, humans and computers can figure out the plant world 2Health News:Together, humans and computers can figure out the plant world 3Health News:Save On Medical Accepted Into Healthbox Accelerator Program 2Health News:Interventional Pain Management Expert Glenn M. Lipton, M.D. Shares Common-Sense Tips for Preventing Chronic Pain 2Health News:Interventional Pain Management Expert Glenn M. Lipton, M.D. Shares Common-Sense Tips for Preventing Chronic Pain 3
... News) -- The time between the start of substance abuse ... than for women, a U.S. government report shows. Researchers ... the first time last year and found that the average ... were primarily being treated for was 15.6 years. The ...
... -- Medical researchers are demonstrating that Office of Naval ... mines can help doctors identify and classify cancer-related cells. ... professor at Duke University and developer of the technology. ... The problem that physicians encounter in analyzing images ...
... By Denise Mann HealthDay Reporter , THURSDAY, Oct. ... likely to cause skin cancer than previously believed. New research ... suggests that the main type of ultraviolet rays used in ... of skin that is most vulnerable to the cancer-causing changes caused ...
... Thomas Jefferson University biochemistry researchers have shown for the ... hormone doesn,t activate and repress genes as once thought. In ... a heme-binding receptor to repress the same genes during the ... the last 20 years, the nuclear receptor known as EcR/Usp ...
... Oct. 6 (HealthDay News) -- As many as one-third of Medicare ... of their life, a new Harvard study finds. But ... a tricky one that can only be decided by the doctor, ... medical director at the American College of Surgeons. Nor is ...
... Where you live could play a larger role in ... study by researchers from the Johns Hopkins Bloomberg School ... low-income neighborhood in Baltimore, Maryland and found that, with ... diabetes, obesity among women and use of health services ...
Cached Medicine News:Health News:Mine-hunting software helping doctors to identify rare cells in human cancer 2Health News:Tanning Beds May Be Even Riskier Than Thought 2Health News:Tanning Beds May Be Even Riskier Than Thought 3Health News:Nuclear receptors battle it out during metamorphosis in new fruit fly model 2Health News:Many Medicare Patients Get Surgeries in Last Year of Life: Study 2Health News:Place, not race, may be a larger determinant of health disparities 2
... The Isoseeds I-125 are brachytherapy sources which ... of localized tumors, especially in the prostate. ... the conclusion of the therapeutic effect, i.e. ... are intended for single use. They are ...
... Four 64 mirrors for complete ... lens rotation. Directly hand held for ... or small holding ring. Small diameter ... gonioscopy without methylcellulose. Advanced technology, multi-layer ...
... Three mirrors of 64, ... small diameter contact surface for ... can be viewed through the ... Multi-layer polymer coating protects mirrors ...
West lacrimal cannula blunt tip with side port....
Medicine Products: